Webcast CME

10th Annual Basic and Clinical Immunology for the Busy Clinician Webcasts: COVID-19 and Immune Mediated Inflammatory Diseases: Immunologic, Clinical, Therapeutic and Preventative Strategies at Two Years

 

COVID-19 autoimmunity, prevention and management

Print this Content

Release date: March 15, 2022
Expiration date: September 15, 2022

Estimated Time of Completion: 2 hours and 15 minutes

Description

The COVID-19 pandemic has had a profound impact on patients with immune-mediated inflammatory diseases (IMIDs). Research is still investigating how the underlying diseases and its therapies, especially targeted agents, affect both the clinical progression of the disease as well as its response to vaccinations. At the same time, significant progress has been made in the early diagnosis, aggressive outpatient management with monoclonal antibodies and antiviral agents, and for hospitalized patients, using immunomodulatory therapies designed to treat IMIDs. Now evidence is accumulating showing that COVID-19 can clearly induce both autoreactivity and autoimmune diseases and may cause long-term symptoms, a syndrome termed “long Covid.”

As a result of the speed and scope of these developments, many practitioners have substantial knowledge gaps regarding these insights into the pathogenesis of COVID-19 and IMIDs, the impact of immunomodulatory therapies and side effects associated with their use, and how to weigh those factors in clinical practice decisions. For this educational activity, the Activity Director and the presenters, all renowned experts in clinical immunology, have identified the following topics as having knowledge and competence gaps among practitioners:

  • Managing COVID-19 in patients with IMIDs
  • Managing IMIDs in the era of COVID-19
  • COVID-19 autoimmunity, prevention, and management
  • Rheumatic diseases and COVID-19

Learning Objectives

  1. Describe the pathogenesis of COVID-19 in patients with immune-mediated inflammatory disease including data on the contributions of both disease-specific factors and targeted therapies for disease progression.
  2. Critically appraise the risks and benefits of biologic therapies and JAK inhibitors in all patients with immune mediated inflammatory diseases in the COVID-19 era.
  3. Summarize recent revisions to major society guidelines for management of IMIDs as they relate to COVID-19.
  4. Describe the research on how COVID-19 may induce or alter autoimmune reactivity in both healthy individuals and patients with pre-existing autoimmune diseases.
  5. Summarize the clinical implications of data on COVID-19 vaccine responses in patients with an IMID.
  6. Describe standards for using monoclonal antibodies in the outpatient management of COVID-19 in high-risk patients with IMIDs.
  7. Summarize recent data on COVID-19 vaccine boosters, effects of immunomodulatory therapies, and implications of viral variants in patients with IMIDs.
  8. Critically appraise the efficacy and side effect data on agents approved or authorized by the FDA as well as agents showing potential for therapy in critically ill patients with COVID-19 who have inflammatory bowel disease, multiple sclerosis, or dermatologic disorders.

Target Audience

The online series is directed to rheumatologists, dermatologists, infectious disease, as well as allergists, clinical immunologists, dermatologists, gastroenterologists, neurologists, specialists in integrative medicine, primary care, nurses, physician assistants, and other health care professionals caring for patients with immunologic diseases.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Cleveland Clinic Center for Continuing Education and Aplastic Anemia & MDS International Foundation. Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians / American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Nurses / American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 2.25 ANCC contact hours.

Physician Assistants / American Academy of PAs (AAPA)

Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Certificate of Participation

A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

American Board of Internal Medicine (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Activity Director and Faculty

Activity Directors

Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Cassandra Calabrese, DO
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Planning Committee

Elizabeth File, MD
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

Alfred Kim, MD, PhD
Director, Washington University Lupus Clinic
Faculty Scholar, Institute for Public Health
Assistant Professor of Medicine, and Pathology & Immunology
Washington University School of Medicine
St. Louis, MO

Jason Knight, MD, PhD
Marvin and Betty Danto Research Professor of Connective Tissue Research
Associate Professor, Department of Internal Medicine, Division of Rheumatology
Associate Director, Lupus Program
University of Michigan Health
Ann Arbor, MI

Jeffrey Sparks, MD, MMSc
Division of Rheumotology, Immunology, and Allergy
Brigham & Women’s Hospital
Boston, MA

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:

Cassandra Calabrese, DO
GSK Advisor or review panel participant
Abbvie Pharmaceuticals Consulting
Sarofi-Regenerun Consulting
Teaching and Speaking


Leonard Calabrese, DO
Astra Zeneca, BMS, Crescendo Teaching and Speaking
GSK, Pfizer, Sanofi Aventis, Novartis, Regeneron, Horizon Pharma Consulting
Genentech/Roche Consulting
Advisor or review panel participant
Teaching and Speaking
UCB, Janssen, Abbvie Pharmaceuticals Consulting
Teaching and Speaking


Alfred Kim, MD
GlaxoSmithKline Consulting
Teaching and Speaking
Principal or Co-Investigator of funded research
Exagen Diagnostics,
Aurinia Pharmaceuticals
Consulting
Teaching and Speaking
Foghorn Therapeutics
Alexion
Principal or Co-Investigator of funded research


Jason Knight, MD
Jazz Pharmaceuticals Grant funding for preclinical research


Jeffrey Sparks, MD
Abbvie Pharmaceuticals                                               Boehringer Ingelheim             
Bristol-Myers Squibb Co.       
Gilead Sciences, Inc.                
Amgen                                          
Janssen Pharmaceuticals, Inc.  
Pfizer, Inc.
Consulting

The following faculty has indicated he has no relationship which, in the context of his presentation(s), could be perceived as a potential conflict of interest:
Elizabeth File, MD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

AstraZeneca Pharmaceuticals
Genentech, Inc.
Janssen Biotech, Inc.
Novartis Pharmaceuticals Corporation


This CME activity was produced by the Cleveland Clinic Center for Continuing Education
and Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology.